Idorsia Ltd

Idorsia Ltd is a biopharmaceutical company headquartered in Allschwil, Switzerland, dedicated to the discovery, development, and commercialization of innovative small molecule medicines. The company's mission is to challenge accepted medical paradigms and address significant unmet medical needs by bringing transformative treatments to patients.

Idorsia's portfolio includes commercially available products such as QUVIVIQ™ (daridorexant) for insomnia and TRYVIO™/JERAYGO™ (aprocitentan) for resistant hypertension. The company maintains a diversified and balanced clinical development pipeline, focusing on multiple therapeutic areas including central nervous system (CNS) disorders, cardiovascular disorders, immunological disorders, and orphan diseases. Additionally, Idorsia possesses a vaccine platform dedicated to the discovery and development of synthetic carbohydrate vaccines to prevent infections.

In recent news, Idorsia reported strong Q1 2026 performance, with QUVIVIQ sales growing 74% year-on-year, and the product is now available in 13 countries. The company also announced positive Phase 2 results for daridorexant in pediatric insomnia. Jean-Paul Clozel assumed the role of interim CEO in March 2026, and Amer Joseph was appointed Chief Medical Officer and Head of Global Clinical Development in April 2026. The company has undertaken restructuring efforts and job cuts in late 2024 to improve financial performance, including exploring the potential sale of rights for its hypertension treatment, Tryvio.